RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.46 and traded as low as $0.82. RedHill Biopharma shares last traded at $0.87, with a volume of 954,952 shares traded.
RedHill Biopharma Price Performance
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The company has a 50-day simple moving average of $0.94 and a two-hundred day simple moving average of $1.46. The stock has a market capitalization of $45.83 million, a price-to-earnings ratio of -0.46 and a beta of 1.86.
Get
RedHill Biopharma alerts:
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last issued its earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative return on equity of 822.29% and a negative net margin of 110.31%. The firm had revenue of $18.24 million for the quarter. During the same period in the prior year, the business earned ($0.53) earnings per share. On average, equities research analysts predict that RedHill Biopharma Ltd. will post -0.95 earnings per share for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of RDHL. Cambridge Investment Research Advisors Inc. bought a new position in shares of RedHill Biopharma in the fourth quarter worth $71,000. HighTower Advisors LLC bought a new position in shares of RedHill Biopharma in the fourth quarter worth $32,000. GSA Capital Partners LLP grew its stake in shares of RedHill Biopharma by 108.4% in the fourth quarter. GSA Capital Partners LLP now owns 218,338 shares of the biotechnology company's stock worth $563,000 after purchasing an additional 113,584 shares in the last quarter. ARK Investment Management LLC bought a new position in shares of RedHill Biopharma in the first quarter worth $2,172,000. Finally, Gagnon Securities LLC grew its stake in shares of RedHill Biopharma by 15.4% in the first quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after purchasing an additional 49,023 shares in the last quarter. Institutional investors own 7.74% of the company's stock.
About RedHill Biopharma
(Get Rating)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Read More
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
